According to Zacks, “Metacrine Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing therapies for patients with liver and gastrointestinal diseases. The company’s program includes MET409 and MET642 which are in clinical trial. Metacrine Inc. is based in San Diego, United States. “
Shares of MTCR opened at $0.49 on Thursday. Metacrine has a 52-week low of $0.35 and a 52-week high of $4.57. The company has a market capitalization of $20.68 million, a PE ratio of -0.24 and a beta of -1.04. The stock has a fifty day simple moving average of $0.50 and a two-hundred day simple moving average of $0.67. The company has a quick ratio of 12.19, a current ratio of 12.19 and a debt-to-equity ratio of 0.29.
Several large investors have recently modified their holdings of the stock. ARCH Venture Management LLC acquired a new stake in shares of Metacrine during the 1st quarter worth about $1,793,000. Renaissance Technologies LLC increased its position in shares of Metacrine by 84.5% during the 1st quarter. Renaissance Technologies LLC now owns 423,100 shares of the company’s stock worth $258,000 after purchasing an additional 193,800 shares during the last quarter. Bank of America Corp DE increased its position in shares of Metacrine by 234.3% during the 4th quarter. Bank of America Corp DE now owns 238,376 shares of the company’s stock worth $161,000 after purchasing an additional 167,072 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Metacrine by 1,236.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 210,435 shares of the company’s stock worth $142,000 after purchasing an additional 194,694 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Metacrine during the 1st quarter worth about $126,000. 13.49% of the stock is owned by hedge funds and other institutional investors.
Metacrine Company Profile (Get Rating)
Metacrine, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc was incorporated in 2014 and is headquartered in San Diego, California.
- Get a free copy of the StockNews.com research report on Metacrine (MTCR)
- Perrigo Stock is a Second Half Expansion Play
- Coty Stock Looks Attractive Down Here
- Blink Charging Stock Looks to Settle Down Here
- Don’t Bet On HP Inc Setting A New High
- The Analysts Like The Fit Of Victoria’s Secret & Co
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Metacrine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metacrine and related companies with MarketBeat.com's FREE daily email newsletter.